Lists of diseases

Tonix Pharmaceuticals Announces Pricing of $15 Million Private Placement of Convertible Redeemable Preferred Stock

Retrieved on: 
Tuesday, October 25, 2022

Each share of Series A and Series B preferred stock is convertible into shares of the Companys common stock at an initial conversion price of $1.00 per share.

Key Points: 
  • Each share of Series A and Series B preferred stock is convertible into shares of the Companys common stock at an initial conversion price of $1.00 per share.
  • Total gross proceeds from the offerings, before deducting discounts, placement agents fees and other estimated offering expenses, is $15 million.
  • The Series B preferred stock permits the holder to cast 2,500 votes per share of Series B preferred stock on such proposal, provided, that such votes must be cast in the same proportions as the shares of common stock and Series A preferred stock are voted on that proposal.
  • The holders of the Series A and Series B preferred stock agreed not to transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of their shares of preferred stock until after the special meeting.

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Retrieved on: 
Tuesday, October 25, 2022

Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.

Key Points: 
  • Proteros will provide access to its entire customizable platform of technologies for early drug discovery guided by the companys experienced discovery teams.
  • The partners will jointly discover lead compounds with the goal of further developing them into first-in-class drugs for intractable genetic diseases.
  • Adrestias carefully validated targets, discovered through their unique platform, and their broad potential in disease applications are an inspiration to Proteros.
  • We are delighted to support Adrestia in their accelerated drug discovery endeavors for a variety of complex targets to treat genetic diseases, said Dr. Debora Konz Makino, Proteros VP Business Unit Discovery Solutions.

NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022

Retrieved on: 
Tuesday, October 25, 2022

MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8, 2022.

Key Points: 
  • MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8, 2022.
  • The companys management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.
  • The webcast will be available for replay for at least 90 days after the event.
  • Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source.

Zhittya Genesis Medicine - Parkinson’s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment

Retrieved on: 
Tuesday, October 25, 2022

LAS VEGAS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced it is hosting an informational luncheon presentation in Jeddah, the Kingdom of Saudi Arabia about its medical discoveries for the treatment of Parkinson’s disease.

Key Points: 
  • Zhittya is now receiving positive human data from their most recent medical research studies suggesting that motor scores of these Parkinsons disease patients have improved 29%-53% after FGF-1 treatment.
  • The two main purposes of the luncheon presentation are to:
    1) Introduce Zhittyas medical breakthrough medicine and provide scientific evidence that the FGF-1 medicine has the very promising potential to treat Parkinsons disease and other brain disorders.
  • We hope that you will be able to attend our presentation and learn more about our possible breakthrough medicine to treat Parkinsons disease.
  • Zhittya Genesis Medicine, Inc. is advancing a group of drugs which trigger the human bodys natural regeneration process.

Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call

Retrieved on: 
Tuesday, October 25, 2022

The Company will host a conference call to review its results at8:30 a.m. Eastern Timethe same day.

Key Points: 
  • The Company will host a conference call to review its results at8:30 a.m. Eastern Timethe same day.
  • The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/h3amkwib .
  • To listen to the conference call on your telephone, participants may register for the call here .
  • Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results.

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

Retrieved on: 
Monday, October 24, 2022

As part of the CTA, Algernon will provide cGMP DMT for the study.

Key Points: 
  • As part of the CTA, Algernon will provide cGMP DMT for the study.
  • In return, Algernon will jointly own intellectual property around the clinical use of DMT arising from the study (IP) developed jointly by Algernon and Yale, and the option to negotiate licenses to both IP developed jointly and IP developed solely by Yale.
  • In addition, the Company will receive data from the study, which may assist in its DMT stroke research program.
  • After careful consideration, we chose to support Dr DSouzas clinical DMT study and work with Yale University, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer

Retrieved on: 
Monday, October 24, 2022

TARRYTOWN, NY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disorder (“ASD”), today announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer.  In this role, Dr. Schwabe will be responsible for overseeing and directing product development activities including pre-clinical, clinical, regulatory and pharmaceutical sciences for PaxMedica’s pipeline products. The initial program underway is targeting antipurinergic drug therapies.   

Key Points: 
  • Howard Weisman, CEO of PaxMedica, commented, We welcome Stefan to PaxMedica, and look forward to his contributions as Chief Medical Officer.
  • Dr. Schwabe worked in the CNS area at Ciba-Geigy, Novo Nordisk, J&J, Novartis and Sanofi in various capacities in clinical development, medical affairs and project management.
  • Most recently, Dr. Schwabe served as Executive Vice President of Research and Development and Chief Medical Officer of Supernus Pharmaceuticals since 2012.
  • Previously, he was the Chief Operating Officer at DemeRx, a privately held biotech company working in the area of addiction.

Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

Retrieved on: 
Monday, October 24, 2022

The completion of enrollment in the main cohort of the EMERALD-1 ahead of target is a significant accomplishment and a testament to the efficiency and commitment of the Morphic development teams, commented Carolyn Soo, PharmD, Vice President of Clinical Operations of Morphic Therapeutic.

Key Points: 
  • The completion of enrollment in the main cohort of the EMERALD-1 ahead of target is a significant accomplishment and a testament to the efficiency and commitment of the Morphic development teams, commented Carolyn Soo, PharmD, Vice President of Clinical Operations of Morphic Therapeutic.
  • This milestone brings us one step closer to realizing this important vision and I would like to thank the patients and investigators for their ongoing commitment this program.
  • Enrollment in the exploratory cohort of up to ~10 patients who have previously failed treatment with vedolizumab is ongoing.
  • Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the 47 integrin for patients with inflammatory bowel disease (IBD).

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs

Retrieved on: 
Tuesday, October 25, 2022

TOKYO and DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Taysha Gene Therapies, Inc. (NASDAQ: TSHA, CEO: RA Session II, “Taysha”) today announced a strategic investment to support the advancement of Taysha’s adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN. The future options to potentially apply Astellas’ global R&D, manufacturing and commercialization capabilities in gene therapy to Taysha’s innovative AAV gene therapy development programs for genetic diseases of the central nervous system (CNS) create the opportunity for the two companies to enhance the development of novel treatment options for patients with Rett syndrome and GAN, who have serious unmet medical needs.

Key Points: 
  • Taysha is engaged in the development of intrathecally-delivered AAV gene therapies for monogenic CNS diseases.
  • To further strategically align Astellas and Taysha, in connection with its equity investment, Astellas will receive one Board observer seat on Tayshas Board of Directors, enabling Taysha to leverage Astellas gene therapy clinical and commercial expertise as Taysha advances TSHA-120 and TSHA-102.
  • Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients.
  • Astellas Gene Therapies will also be advancing additional Astellas gene therapy programs toward clinical investigation.

Bionano Genomics Announces Global User Event at Bionano Laboratories Before American Society of Human Genetics (ASHG) Annual Meeting

Retrieved on: 
Monday, October 24, 2022

SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the company will host a Meet the User event today, October 24, 2022, at its new CLIA-certified Bionano Laboratories facility in advance of the American Society of Human Genetics(ASHG) Annual Meeting 2022.

Key Points: 
  • SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the company will host a Meet the User event today, October 24, 2022, at its new CLIA-certified Bionano Laboratories facility in advance of the American Society of Human Genetics(ASHG) Annual Meeting 2022.
  • The days programming will includea tour ofthe state-of-the-artBionano Laboratories, witha hands-on demonstration of the OGM workflow by experienced technologists.
  • Our user meeting is a terrific opportunity to showcase Bionano Laboratories to our customers and interested prospects.
  • The response to this event has been tremendous, with over fifty attendees traveling from countries across the world.